Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith Sells 4,767 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 4,767 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total value of $1,926,535.38. Following the transaction, the chief executive officer now owns 2,925,060 shares of the company’s stock, valued at approximately $1,182,133,748.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Price Performance

AXON stock opened at $421.80 on Monday. The stock has a market capitalization of $31.83 billion, a price-to-earnings ratio of 123.33, a price-to-earnings-growth ratio of 10.84 and a beta of 0.94. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 52-week low of $192.63 and a 52-week high of $422.33. The stock’s fifty day simple moving average is $365.66 and its 200-day simple moving average is $323.62.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the company posted $0.80 EPS. The company’s quarterly revenue was up 34.5% compared to the same quarter last year. Equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AXON. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Barclays increased their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Bank of America initiated coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price for the company. Finally, Northland Securities boosted their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $365.38.

Hedge Funds Weigh In On Axon Enterprise

A number of large investors have recently bought and sold shares of AXON. Blue Trust Inc. grew its stake in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares during the period. Trivant Custom Portfolio Group LLC acquired a new position in Axon Enterprise in the first quarter valued at $31,000. Quent Capital LLC grew its position in Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares during the period. First PREMIER Bank acquired a new stake in Axon Enterprise during the first quarter worth about $33,000. Finally, Rise Advisors LLC raised its holdings in shares of Axon Enterprise by 49.0% in the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 47 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.